SCHEMBL5028754

SCHEMBL5028754

Cc1ccc(CN(C)CCO)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PYCR1 P32322 2/20 0.53
NPSR1 Q6W5P4 1/20 0.50
SPHK1 Q9NYA1 1/20 0.43
CARM1 Q86X55 1/20 0.42
PRMT6 Q96LA8 1/20 0.42
PRMT8 Q9NR22 1/20 0.42
HSD17B10 Q99714 1/20 0.42
PDCD1 Q15116 1/20 0.42
CD274 Q9NZQ7 1/20 0.42
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 2/20 0.42
CHEK1 O14757 1/20 0.41
KCNH2 Q12809 1/20 0.40
ACKR3 P25106 1/20 0.39
SIGMAR1 Q99720 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
MEN1 O00255 1/20 0.38
LMNA P02545 1/20 0.38
KMT2A Q03164 1/20 0.38
CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14308432 0.88 PYCR1 (0.50) PYCR1NPSR1CARM1PRMT6PRMT8
SCHEMBL8251026 0.83 KDM4E (0.50) PYCR1NPSR1SPHK1CARM1PRMT6
SCHEMBL16312619 0.82 PYCR1 (0.65) PYCR1NPSR1KDM4EALDH1A1KCNH2
SCHEMBL3146657 0.82 MAPT (0.47) PYCR1SPHK1CARM1PRMT6PRMT8
SCHEMBL17195529 0.82 CARM1 (0.41) PYCR1SPHK1CARM1PRMT6PRMT8
SCHEMBL23146146 0.82 CARM1 (0.41) PYCR1NPSR1SPHK1CARM1PRMT6
SCHEMBL8392169 0.82 PYCR1 (0.55) PYCR1KDM4EALDH1A1SIGMAR1
SCHEMBL9826270 0.82 PYCR1 (0.55) PYCR1CARM1PRMT6PRMT8HSD17B10
SCHEMBL308505 0.82 KDM4E (0.62) PYCR1CARM1PRMT6PRMT8HSD17B10
SCHEMBL10065870 0.81 PYCR1 (0.55) PYCR1NPSR1CARM1PRMT6PRMT8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1983992-A2 2-IMINO-BENZIMIDAZOLES Abbott Laboratories (US) 2008-10-29 EP disclosed
US-7384952-B2 Pyrazolopyrimidine compound and a process for preparing the same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-06-10 US disclosed
US-7384952-B2 Pyrazolopyrimidine compound and a process for preparing the same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-06-10 US disclosed
US-20070232673-A1 2-Imino-benzimidazoles ABBOTT LABORATORIES 2007-10-04 US disclosed
US-20070232673-A1 2-Imino-benzimidazoles ABBOTT LABORATORIES 2007-10-04 US disclosed
US-20070232673-A1 2-Imino-benzimidazoles ABBOTT LABORATORIES 2007-10-04 US disclosed
WO-2007084728-A2 2-IMINO-BENZIMIDAZOLES ABBOTT LABORATORIES (US) 2007-07-26 WO disclosed
WO-2007084728-A2 2-IMINO-BENZIMIDAZOLES ABBOTT LABORATORIES (US) 2007-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232673-A1 2-Imino-benzimidazoles CYP2C19, UGT2B7, UGT2B17 PYCR1 1071/4885NPSR1 4254/4885SPHK1 2910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.